The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Limitations of standard clinical trial endpoints when reporting outcomes in older adults with DLBCL
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the limitations of traditional clinical trial endpoints for assessing older adults with diffuse large B-cell lymphoma (DLBCL). Dr Torka highlights the importance of considering patient-reported outcomes and quality-of-life measures to provide a more comprehensive understanding of treatment efficacy. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so, you know, most clinical trials have overall survival, progression-free survival, and response rate as their endpoints. And while they are very important, an 85-year-old who’s living independently in the community may value their independence as equally, basically their independence may be equally as important to them as disease control. So I think in the future, you know, incorporating endpoints like time to toxicity and also patient-reported outcomes such as what we call PRO-CTCAE, which is patient-reported adverse event profile, are going to be really important in capturing for these clinical trials...
Yeah, so, you know, most clinical trials have overall survival, progression-free survival, and response rate as their endpoints. And while they are very important, an 85-year-old who’s living independently in the community may value their independence as equally, basically their independence may be equally as important to them as disease control. So I think in the future, you know, incorporating endpoints like time to toxicity and also patient-reported outcomes such as what we call PRO-CTCAE, which is patient-reported adverse event profile, are going to be really important in capturing for these clinical trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
